Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.77 |
| ▸ | PARP1 | P09874 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863462 | 0.87 | AR (1.00) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL29349943 | 0.84 | LMNA (1.00) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL1789242 | 0.84 | LMNA (1.00) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL8154178 | 0.84 | AR (0.77) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL12955526 | 0.84 | AR (0.77) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL12955544 | 0.84 | AR (0.77) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL12955341 | 0.84 | AR (0.77) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL13239966 | 0.84 | PARP1 (0.68) | ARPARP1LMNAENPP1 | |
| SCHEMBL12955362 | 0.84 | PARP1 (0.70) | ARPARP1LMNAENPP1CYP3A4 | |
| SCHEMBL12955373 | 0.84 | LMNA (0.68) | ARPARP1LMNAENPP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102485721-A | Substituted 2,3-phthalazinone compounds and application thereof | SUZHOU KERUIGE MEDICAL TECHNOLOGY CO LTD | 2012-06-06 | — | — | CN | disclosed |
| EP-1330442-B1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARM LTD (GB) | 2011-01-19 | — | — | EP | disclosed |
| US-7750006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-07-06 | — | — | US | disclosed |
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
| US-6180629-B1 | INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION, INCLUDING PRECANCEROUS AND CANCEROUS LESIONS | CELL PATHWAYS, INC. | 2001-01-30 | — | — | US | disclosed |
| US-5464838-A | Aminocarboxylic acid derivatives having antiallergic/antiasthmatic effect and a process for their preparation | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1995-11-07 | — | — | US | disclosed |
| EP-0564805-A1 | (4-benzylphthalazin-1(2H)-on-2-yl)aminocarboxylic acids having antiallergic/antihistaminic activity and process for their production | ASTA Medica Aktiengesellschaft (DE) | 1993-10-13 | — | — | EP | disclosed |
| EP-0289881-A2 | 2-Aminoalkyl-4-benzyl-1-(2H)-phthalazinone derivatives | ASTA Medica Aktiengesellschaft (DE) | 1988-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | AR 853/4885PARP1 2415/4885LMNA 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.